Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;55(9):575-585.
doi: 10.1358/dot.2019.55.9.3039669.

Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors

K M Fenn  1 , K Kalinsky  2
Affiliations
Review

Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors

K M Fenn et al. Drugs Today (Barc). 2019 Sep.

Abstract

Patients with metastatic triple-negative breast cancer (mTNBC) that has progressed on first-line therapy have a poor prognosis with limited therapeutic options. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate (ADC) that has shown promising efficacy in mTNBC. SG is comprised of SN-38, the active metabolite of irinotecan, conjugated via a hydrolyzable linker to the humanized RS7 antibody targeting trophoblast cell surface antigen 2 (Trop-2), a glycoprotein that is expressed at high levels in many epithelial solid tumors. It has received breakthrough therapy status by the U.S. Food and Drug Administration (FDA) for the treatment of patients with pretreated mTNBC. In this review, we summarize available data regarding the pharmacology, pharmacokinetics, safety and efficacy of SG and describe ongoing and future clinical studies investigating this agent.

Keywords: Antibody-drug conjugates; IMMU-132; Inhibitors of Trop-2; Metastatic triple-negative breast cancer; Sacituzumab govitecan; Treatment of solid tumors.

PubMed Disclaimer

References

    1. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15 Pt 1): 4429–34. - PubMed
    1. Malorni L, Shetty PB, De Angelis C et al. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat 2012, 136(3): 795–804. - PMC - PubMed
    1. Schmid P, Adams S, Rugo HS et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018, 379(22): 2108–21. - PubMed
    1. Cubas R, Li M, Chen C, Yao Q Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009, 1796(2): 309–14. - PubMed
    1. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 2015, 6(26): 22496–512. - PMC - PubMed

MeSH terms